About PEMAZYRE — 3 of 3

PEMAZYRE was studied in the FIGHT–202 study

FIGHT–202 was a multicentre, open-label, single-arm study to evaluate the efficacy and safety of PEMAZYRE in previously treated patients with locally advanced/metastatic or surgically unresectable CCA1

FIGHT–202 STUDY DESIGN1

Patients

Adults with locally advanced/metastatic or surgically unresectable CCA

Progressed after ≥1 prior therapy

FGFR2 fusion or rearrangement, as determined by test performed at central laboratory

Cohort A

(N=108)
105 patients had intrahepatic disease

Dosing

Patients received PEMAZYRE 13.5 mg once daily in 21-day cycles (14 days on, followed by 7 days off) until disease progression or unacceptable toxicity

Major efficacy outcomes

ORR (primary endpoint) and DOR, as determined by independent review committee according to RECIST v1.1

 eDetail.about.about3.modal.trigger.iconAlt

Baseline
demographics/
characteristics